参考文献/References:
[1] Rusinek H, De Santi S, Frid D, et al. Regional brain atrophy rate predicts future cognitive decline:6-year longitudinal MR imaging study of normal aging. Radiology, 2003, 229(3):691-696.
[2] Dimou E, Booij J, Rodrigues M, et al. Amyloid PET and MRI in Alzheimer’s disease and mild cognitive impairment. Curr Alzheimer Res, 2009, 6(3):312-319.
[3] Valotassiou V, Archimandritis S, Sifakis N, et al. Alzheimer’s disease:speet and pet tracers for beta-amyloid imaging. CurtAlzheimer Res, 2010, 7(6):477-486.
[4] Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol, 2004, 55(3):306-319.
[5] Shin J, Lee S Y, Kim S J, et al. Voxel-based analysis of Alzheimer’s disease PET imaging using a triplet of radiotraeers:PIB, FDDNP, and FDG. Neuroimage, 2010, 52(2):488-496.
[6] Wong D F, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer Disease using the radiolig and -SF-AV-45(Flobetapir F 18). J Nuel Med, 2010, 51(6):913-920.
[7] Liu Y, Zhu L, Plössl K, et al. Optimization of automated radiosynthesis of[18SF]AV-45:a new PET imaging agent for Alzheimer’s disease. Nucl Med Biol, 2010, 37(8):917-925.
[8] Lin K, Hsu WC, Hsiao IT, et al. Whole-body biodistribution and brain PET imaging with[18F]AV-45, a novel amyloid imaging agent——a pilot study. Nuel Med Biol, 2010, 37(4):497-508.
[9] Clark CM, Schneider JA, Bedell B J, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA, 2011,305(3):275-283.
[10] Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer disease beta-amyloid with[11C]SB-13 PET. Am J Geriatr Psychiatry, 2004, 12(6):584-595.
[11] Kudo Y, Okamura N, Furumoto S, et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole:a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer’s disease patients. J Nucl Med, 2007, 48(4):553-561.
[12] Swahn B, Wensbo D, Sandell J, et al. Synthesis and evaluation of 2-pyridylbenzothiazole, 2-pyridylbenzoxazole and 2-pyridylbenzofuran derivatives as 11C-PET imaging agents for beta-amyloid plaques. Bioorg Med Chem Lett, 2010, 20(6):1976-1980.
[13] Johnson AE, Jeppsson F, Sandell J, et al. AZD2184:a radioligand for sensitive detection of beta-amyloid deposits. J Neurochem, 2009, 108(5):1177-1186.
[14] Koole M, Lewis DM, Buckley C, et al. Whole-Body biodistribution and radiation dosimetry of 18SF-GE067:a radioligand for in viwo brain amyloid imaging. J Nucl Med, 2009, 50(5):818-822.
[15] Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer:proof of mechanism. Lancet Neurol, 2008, 7(2):129-135.
[16] Cheng Y, Ono M, Kimura H, et al. Fluorinated benzofuran derivatives for PET imaging of 13-amyloid plaques in Alzheimer’s disease brains. ACS Med Chemistry Lett, 2010, 1(7):321-325.
[17] One M, Cheng Y, Kimura H, et al. Novel 18F-labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging of β-amyloid plaques in Alzheimer’s brains. J Med Chem, 2011, 54(8):2971-2979.
[18] Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology, 1992, 42(3 Pt 1):631-639.
[19] Ceravolo R, Borghetti D, Kiferle L, et al. CSF phosporylated TAUprotein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer’s disease. Brain Res Bull, 2008, 76(1-2):80-84.
[20] Shin J, Lee SY, Kim SH, et al. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer’s disease. Neuroimage, 2008, 43(2):236-244.
[21] Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med, 2006, 355(25):2652-2663.
[22] Powell MR, Smith GE, Knopman DS, et al. Cognitive measures predict pathologic Alzheimer disease. Arch Neurol, 2006, 63(6):865-868.
[23] Fodero-Tavoletti MT, Okamura N, Furumoto S, et al. 18F-THK523:a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain, 2011, 134(Pt4):1089-1100.
[24] Okamura N, Suemoto T, Furumoto S, et al. Quinoline and benzimidazole derivatives:candidate probes for in vivo imaging of tau pathology in Alzheimer’s disease. J Neurosci, 2005, 25(47):10857-10862.
[25] Velasco A, Fraser G, Delobel P, et al. Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB[(trans, trans)-1-fluoro-2,5-bis (3-hydroxycarbonyl-4-hydroxy) styrylbenzene]. FEBS Lett, 2008, 582(6):901-906.
[26] Mohorko N, Repov?G, Popovic M, et al. Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples. J Neuropathol Exp Neurol, 2010, 69(4):405-414.
[27] Ono M, Hayashi S, Matsumura K, et al. Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer’s brains. ACS Chem Neurosci, 2011, 2(5):269-275.
[28] Honson NS, Johnson RL, Huang W, et al. Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol Dis, 2007, 28(3):251-260.
[29] Matsumura K, Ono M, Hayashi S, et al. Phenyldiazenyl benzothiazole derivatives as probes for in vivo imaging of neurofibrillary tangles in Alzheimer’s disease brains. Med Chem Comm, 2011, 2(7):596-600.
[30] Mosconi L, Berti V, Glodzik L, et al. Pre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging. J Alzbeimers Dis, 2010, 20(3):843-854.
[31] Kippenhan JS, Barker WW, Pascal S, et al. Evaluation of a neuralnetwork classifier for PET scans of normal and Alzheimer’s disease subjects. J Nucl Med, 1992, 33(8):1459-1467.
[32] Mosconi L, Tsui WH, Herholz K, et al. Multicenter Standardized 11F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s Disease, and other dementias. J Nucl Med, 2008, 49(3):390-398.
[33] Li Y, Rinne JO, Mosconi L, et al. Regional analysis of FDG andPIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease. Eur J Nucl Med Mol Imaging, 2008, 35(12):2169-2181.
[34] Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer’s disease. Neurobiol Aging, 2012, 33(1):191-198.
[35] Berti V, Os orio RS, Mosconi L, et al. Early detection of Alzheimer’s disease with PET imaging. Neurodegener Dis, 2010, 7(1-3):131-135.
[36] Ellis JR, Nathan PJ, Villemagne VL, et al. Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2)nicotinic receptors in early Alzheimer’s disease as measured in vivo by 2-[18F] fluoro-A-85380 PET. Psychopharmacology (Berl), 2009, 202(1-3):79-91.
[37] Ellis JR, Villemagne VL, Nathan PJ, et al. Relationship between nicotinic receptors and cognitive function in early Alzheimer’s disease:a 2-[18F]fluoro-A-85380 PET study. Neurobiol Learn Mere, 2008, 90(2):404-412.
[38] Gao M, Wang M, Hutehins GD, et al.[11C] Dimebon, radiosynthesis and lipophilieity of a new potential PET agent for imaging of Alzheimer’s disease and Huntington’s disease. Bioorg Med Chem Lett, 2010, 20(8):2529-2532.
[39] Santhosh L, Estok KM, Vogel RS, et al. Regional distribution and behavioral correlates of 5-HT(2A) receptors in Alzheimer’s disease with[ISF]deuteroahanserin and PET. Psychiatry Res, 2009, 173(3):212-217.
[40] Truchot L, Costes N, Zimmer L, et al. A distinct[18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer’s disease. Neuroimage, 2008, 40(3):1251-1256.
[41] Marner L, Frokjaer VG, Kalbitzer J, et al. Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer’s disease:a combined[11C]DASB and[18F]altanserin-PET study. Neurobiol Aging, 2012, 33(3):479-487.
[42] Fukumitsu N, Ishii K, Kimura Y, et al. Adenosine A (l) receptors using 8-dicyclopropylmethyl-1-[11C]methyl-3-propylxanthine PET in Alzheimer’s disease. Ann Nucl Med, 2008, 22(10):841-847.
[43] Edison P, Archer HA, Gerhard A, et al. Microglia, amyloid, and cognition in Alzheimer’s disease:An[11C](R)PKI 1195-PET and[11C]PIB-PET study. Neurobiol Dis, 2008, 32(3):412-419.
[44] Vennetl S, Lopresti BJ, Wang C, et al. PK11195 labels activated microglia in Alzheimer’s disease and in vivo in a mouse model using PET. Neurobiol Aging, 2009, 30(8):1217-1226.
[45] Esposito G, Giovacchini G, Liow JS, et al. Imaging neuroinflammation in Alzheimer’s disease with radiolabeled arachidonic acid and PET. J Nucl Med, 2008, 49(9):1414-1421.
相似文献/References:
[1]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[2]张晓,兰晓莉,胡帆,等.点击化学在分子影像学中的应用和进展[J].国际放射医学核医学杂志,2016,40(3):196.[doi:10.3760/cma.j.issn.1673-4114.2016.03.008]
Zhang Xiao,Lan Xiaoli,Hu Fan,et al.Applications and advances of click chemistry in molecular imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):196.[doi:10.3760/cma.j.issn.1673-4114.2016.03.008]
[3]解朋,黄建敏,张芳,等.99Tcm-MAG3-isoDGR-2C分子探针的制备与体内分布的实验研究[J].国际放射医学核医学杂志,2016,40(5):345.[doi:10.3760/cma.j.issn.1673-4114.2016.05.004]
Xie Peng,Huang Jianmin,Zhang Fang,et al.Labeling MAG3-isoDGR-2C with 99Tcm and its biodistribution in mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):345.[doi:10.3760/cma.j.issn.1673-4114.2016.05.004]
[4]汪文霞,兰晓莉,张永学.HER2的表达及其分子影像的研究进展[J].国际放射医学核医学杂志,2016,40(5):363.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
Wang Wenxia,Lan Xiaoli,Zhang Yongxue.Research and development of HER2 expression molecular imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):363.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
[5]安淑娴,宋少莉,黄钢.放射性核素标记的凋亡显像剂的研究进展[J].国际放射医学核医学杂志,2015,39(6):470.[doi:10.3760/cma.j.issn.1673-4114.2015.06.008]
An Shuxian,Song Shaoli,Huang Gang.Recent advances in apoptosis imaging using radionuclide-labeled tracers[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):470.[doi:10.3760/cma.j.issn.1673-4114.2015.06.008]
[6]李帅,李剑明.动脉粥样硬化易损斑块放射性核素标记分子探针的研究进展[J].国际放射医学核医学杂志,2015,39(1):80.[doi:10.3760/cma.j.issn.1673-4114.2015.01.017]
Li Shuai,Li Jianming.Research progress of molecular probes labeled with radionuclide for imaging of atherosclerosis vulnerable plaque[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):80.[doi:10.3760/cma.j.issn.1673-4114.2015.01.017]
[7]林潇,唐明灯.靶向表皮生长因子受体分子探针研究进展[J].国际放射医学核医学杂志,2015,39(1):85.[doi:10.3760/cma.j.issn.1673-4114.2015.01.018]
Lin Xiao,Tang Mingdeng.Research progresses on molecular probes targeting epidermal growth factor receptor[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):85.[doi:10.3760/cma.j.issn.1673-4114.2015.01.018]
[8]段小艺,李淼,王黎,等.阿尔茨海默病PET正电子药物应用与研究进展[J].国际放射医学核医学杂志,2014,38(5):318.[doi:10.3760/cma.j.issn.1673-4114.2014.05.010]
Duan Xiao-yi,Li Miao,Wang Li,et al.Application and research progress of PET positron tracers associated with Alzheimer disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):318.[doi:10.3760/cma.j.issn.1673-4114.2014.05.010]
[9]王新艳,管一晖.阿尔茨海默病的影像学诊断进展[J].国际放射医学核医学杂志,2013,37(1):52.[doi:10.3760/cma.j.issn.1673-4114.2013.01.014]
WANG Xin-yan,GUAN Yi-hui.The advancement in Alzheimer disease of imaging diagnosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):52.[doi:10.3760/cma.j.issn.1673-4114.2013.01.014]
[10]王颖,蔡莉,李彦生,等.11C-PIB PET在不同时期阿尔茨海默病中的研究进展[J].国际放射医学核医学杂志,2013,37(6):378.[doi:10.3760/cma.j.issn.1673-4114.2013.06.013]
WANG Ying,CAI Li,LI Yan-sheng,et al.Application of 11C-PIB PET in different period of the Alzheimer disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):378.[doi:10.3760/cma.j.issn.1673-4114.2013.06.013]
[11]蔡汉成,尹端沚,张岚,等.早期诊断阿尔茨海默病的PET分子探针[J].国际放射医学核医学杂志,2006,30(4):202.
CAI Han-cheng,YIN Duan-zhi,ZHANG Lan,et al.PET molecular probes for early detection of Alzheimer’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(5):202.